RF ablation for varicose veins: VNUS Medical Technologies' ClosureFAST radiofrequency ablation system for treatment of venous reflux, the underlying cause of symptomatic varicose veins, is "significantly superior" to endovenous laser treatment as measured by quality-of-life and post-procedural recovery parameters, according to results of the 69-patient RECOVERY multicenter, randomized study by Jose Almeida, Miami Vein Center, et al, published in the June issue of the Journal of Vascular & Interventional Radiology. The patients treated with ClosureFAST had less postoperative pain and bruising and better reduction of symptoms than the laser-treated patients as early as two days post-procedure and continued to show better outcomes two weeks after the treatment; however, equalization in most parameters was observed between the two groups by one month. All quality-of-life parameters were significantly better, and minor complications were five times less common, in the ClosureFAST group. Covidien recently signed a deal to acquire VNUS for $440 million (1"The Gray Sheet" May 11, 2009, p. 15)
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Predictability, proportionality, stability, harmonization and simplification offer the right way forward to address the challenging unintended effects of the EU medical device regulations, the European Commission’s head of devices tells the EU’s largest annual medtech conference.
German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.
Medtronic expects operating profit to grow approximately 7% in fiscal 2026, excluding tariff impacts. If tariffs materialize at the upper end of the projected range, operating profit growth could drop by 2.2 to 3.2 percentage points.
